Luis Borges - Mar 21, 2023 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role
Chief Scientific Officer
Signature
/s/ Michael Diem, Attorney-in-Fact
Stock symbol
IPSC
Transactions as of
Mar 21, 2023
Transactions value $
-$179,128
Form type
4
Date filed
3/23/2023, 07:31 PM
Previous filing
Feb 6, 2023
Next filing
Apr 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IPSC Common Stock Options Exercise $65.5K +63.6K +145.41% $1.03 107K Mar 21, 2023 Direct
transaction IPSC Common Stock Sale -$240K -63.6K -59.25% $3.77 43.8K Mar 21, 2023 Direct F1
transaction IPSC Common Stock Options Exercise $67.7K +65.7K +150.17% $1.03 109K Mar 22, 2023 Direct
transaction IPSC Common Stock Sale -$245K -65.7K -60.03% $3.72 43.8K Mar 22, 2023 Direct F2
transaction IPSC Common Stock Options Exercise $228K +221K +504.98% $1.03 265K Mar 23, 2023 Direct
transaction IPSC Common Stock Sale -$55.4K -15.6K -5.89% $3.55 249K Mar 23, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IPSC Stock Option (right to buy) Options Exercise $0 -63.6K -17.78% $0.00 294K Mar 21, 2023 Common Stock 63.6K $1.03 Direct F3
transaction IPSC Stock Option (right to buy) Options Exercise $0 -65.7K -22.34% $0.00 228K Mar 22, 2023 Common Stock 65.7K $1.03 Direct F3
transaction IPSC Stock Option (right to buy) Options Exercise $0 -221K -96.74% $0.00 7.45K Mar 23, 2023 Common Stock 221K $1.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.57 to $3.79, inclusive.
F3 The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.